Clinical Significance of the Interleukin 24 mRNA Level in Head and Neck Squamous Cell Carcinoma and Its Subgroups: An In Silico Investigation

Qiu, Lanlan; Zhang, Xiao-Guohui; Chen, Gang; Dang, Yi‐Wu; Huang, Zhi‐Guang; Li, Mingxuan; Liang, Yao; Huang, Su-Hua; Tang, Xiao‐Zhun; Chen, Xiaoxia; Wei, Hongyu; Wu, Huayu

doi:10.1155/2020/7042025

Cited by 4 publications

(1 citation statement)

References 36 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If secreted by tumor cells, it has been associated with advanced tumor stage. Furthermore, IL24 belongs to the IL10 gene family that possess antitumor properties including inhibition of tumor angiogenesis and induction of tumor cell apoptosis [ 52 ]. In the same study, interleukins IL18 and IL36β both belonging to the IL1 family, were on the other hand downregulated [ 44 ], again emphasizing immunoreactions not necessarily pointing in one direction.…”

Section: Immunological Responses To Laser: Clinical Evidencementioning

confidence: 99%

Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

Omland

Wenande

Svane

et al. 2021

Cancers

View full text Add to dashboard Cite

The role of the immune system in cancer growth is well recognized and the development of immunotherapy represents a breakthrough in cancer treatment. Recently, the use of systemic immunotherapy was extended to keratinocyte carcinoma (KC), specifically locally advanced and metastasizing basal and squamous cell carcinoma. However, since most KC lesions are non-aggressive, systemic treatment with associated side effects is rarely justified. Conversely, topical immunotherapy with imiquimod remains restricted to premalignant and superficial lesions. Use of laser in the treatment of KC has evolved from physical tumor destruction and laser-assisted drug delivery to laser-mediated immune modulation. Evidence indicates that laser monotherapy can lead to immune cell infiltration, tumor reduction and resistance to tumor re-inoculation. Combining laser with immunotherapeutic agents, termed laser immunotherapy (LIT), may further potentiate immune activation and tumor response. Studies on LIT show not only direct anti-tumor effects but systemic adaptive immunity, illustrated by the prevention of tumor recurrence and regression in distant untreated tumors. These findings imply a therapeutic potential for both local and metastatic disease. This work provides rationales for immune-based treatment of KC and presents the current status of KC immunotherapy. Aiming to expand the field of KC immunotherapy, the review discusses the literature on immune activation following laser monotherapy and LIT.

show abstract

Section: Immunological Responses To Laser: Clinical Evidencementioning

confidence: 99%